Compare Fortinet Inc (FTNT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Recursion Pharmaceuticals Inc — how do they compare? Fortinet Inc trades at $191.89 (market cap $138.75B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: Fortinet Inc is far larger — about 64.8× Recursion Pharmaceuticals Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FTNT | RXRX | |
|---|---|---|
Market Cap | $138.75B | $2.14B |
Volume | 2,956,908 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $191.27 | $6.79 |
52-Week Low | $75.23 | $2.84 |
Typical Hold Time | 72 Days | 22 Days |
Enterprise Value | $135.17B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTNT trades at $189.28, down 1.04% on the day but near its 52-week high, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $6.80B in 2025, supported by an 80.2% gross margin and robust cash flow from operations of $2.59B. Analyst sentiment is mixed, with 42% buy ratings but a consensus price target of $158.64 below the current price.
Outlook remains positive due to cybersecurity demand and AI-driven growth, but high valuation ratios (P/E of 66.82) pose risks. Competition and execution challenges could pressure margins. Institutional interest is strong, with recent position increases noted in SEC filings. The stock's momentum depends on continued earnings outperformance and market share gains in data center security.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
